Posted by Michael Wonder on 17 Jan 2024
Dupixent (dupilumab) US label updated with data further supporting use in atopic dermatitis with moderate to severe hand and foot involvement
16 January 2024 - Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult to treat population.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has updated the label for Dupixent (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate to severe hand and/or foot involvement.
